AXSM logo

AXSM Axsome Therapeutics, Inc.

NASDAQ Global Market · Biotechnology · Healthcare

$134.01
-1.94 (-1.43%)

Axsome Therapeutics, Inc. is a biopharmaceutical company dedicated to discovering and advancing innovative treatments for a range of central nervous system (CNS) disorders within the United States. Its robust product pipeline features several promising candidates, including: AXS-05, an investigational therapy currently being developed for major depressive disorder and treatment-resistant depressio…

Market Cap: $7.05Bwww.axsome.com

Price

$215.77-3.54%
$210.13$225.14$240.16$255.17
May 4Aug 11

Social Signal Score

54
5d
50
1 mentions
+0.0%
30d
56
17 mentions
+0.0%
60d
55
23 mentions
+0.0%
90d
56
43 mentions
+0.0%
rss: 12 · marketaux: 2 · news: 29

Analyst Ratings

27 analysts
Buyconsensus
Strong Buy 0Buy 26Hold 1Sell 0Strong Sell 0
Avg price target$279.25+108.4%
Low $238Median $267.5High $380
Current Consensus

Revenue

$259.69M
$0.00$86.56M$173.13M$259.69M
Dec 2016Sep 2026

Analyst Estimates

FY2025
$-3.76
$-4.23–$-3.41
12 analysts
FY2026
$-2.54
$-3.09–$-0.44
15 analysts
FY2027
$3.52
$-3.46–$7.07
15 analysts

Consensus estimates, not results. Via Financial Modeling Prep.

Company Profile

CEO
Herriot Tabuteau
Sector
Healthcare
Industry
Biotechnology
Employees
1,346
Beta
0.60
Country
US
Piotroski score
3 / 9 (Weak)
Altman Z-score
4.14
www.axsome.com